{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:12:58Z","timestamp":1787019178004,"version":"build-2736575974"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"\n Background<\/jats:title>\n \n Lecanemab and donanemab are anti-amyloid-\u03b2 monoclonal antibodies recently approved in the United States and Europe for the treatment of early Alzheimer's disease (AD). Their modest clinical benefit, safety profile, and cost raise debate about real-world applicability. Fortasyn Connect (Souvenaid\n TM<\/jats:sup>\n ), a multi-nutrient intervention, has shown potential clinical benefits in prodromal AD.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To compare the clinical effect sizes (Cohen's\n d<\/jats:italic>\n ) and estimated months of preserved independence in instrumental activities of daily living (IADLs) for lecanemab, donanemab, and Souvenaid\u2122, based on published pivotal clinical trial data.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Cohen's\n d<\/jats:italic>\n on the Clinical Dementia Rating\u2013Sum of Boxes (CDR-SB) was computed using standardized mean differences and 95% confidence intervals (CIs) derived from published trials. Times of functional independence were estimated using the Hartz approach.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Point estimates of Cohen's\n d<\/jats:italic>\n effect sizes on CDR-SB were \u22120.34, \u22120.33, and \u22120.52 for lecanemab, donanemab, and Souvenaid\u2122, respectively, with no statistically significant differences between drugs. Estimated gains in IADL independence were 10 months for lecanemab, 8 months for donanemab, and 27 months for Souvenaid\u2122.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Despite differences in study designs, Souvenaid\n TM<\/jats:sup>\n demonstrated comparable clinical efficacy with superior safety, accessibility, and cost profile. These findings support further evaluation of Souvenaid\n TM<\/jats:sup>\n as a non-invasive, scalable option in early AD management.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/13872877251406221","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T17:28:32Z","timestamp":1766424512000},"page":"1258-1263","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing clinical effect sizes of Souvenaid\n TM<\/sup>\n , lecanemab, and donanemab in early Alzheimer\u2019s disease"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8524-0315","authenticated-orcid":false,"given":"Vincenzo","family":"Solfrizzi","sequence":"first","affiliation":[{"name":"Department of Interdisciplinary Medicine (DIM), \u201cCesare Frugoni\u201d Internal and Geriatric Medicine and Memory Unit, University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0327-7262","authenticated-orcid":false,"given":"Bruno P","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"Research & Development, Chiesi Farmaceutici, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14114"},{"key":"e_1_3_3_5_2","unstructured":"Eisai News Release. New clinical data demonstrates three years of continuous treatment with dual-acting LEQEMBI\u00ae (lecanemab-irmb) continues to significantly benefit early Alzheimer\u2019s disease patients presented at AAIC 2024 July 31 2024 https:\/\/www.eisai.com\/news\/2024\/news202456.html (accessed 10 October 2025)."},{"key":"e_1_3_3_6_2","unstructured":"Hicks R. NICE Rejects Alzheimer\u2019s drugs over limited benefit for cost. Medscape https:\/\/www.medscape.com\/viewarticle\/nice-rejects-alzheimers-drugs-over-limited-benefit-cost-2025a1000gej?form=fpf (Medscape 2025 June 19)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331941"},{"key":"e_1_3_3_8_2","article-title":"Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease","volume":"11","author":"Hartz SM","year":"2025","unstructured":"Hartz SM, Schindler SE, Streitz ML, et al. Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease. Alzheimers Dement (N Y) 2025; 11: e70033.","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01296-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1495"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60461-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302368"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30332-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)03320-1"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7427(03)00024-8"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-130998"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2013.00863"},{"key":"e_1_3_3_20_2","unstructured":"Jackson M. Eisai forecasts 73% Leqembi sales rise in FY25 as demand expands https:\/\/insights.citeline.com\/scrip\/business\/earnings\/eisai-forecasts-73-leqembi-sales-rise-in-fy25-as-demand-expands-YSVE5J4KVBC37MMV6HBVHDNZYE\/ (Scrip May 16 2025)."}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251406221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251406221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251406221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:51Z","timestamp":1777370991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251406221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/13872877251406221"],"URL":"https:\/\/doi.org\/10.1177\/13872877251406221","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}